KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $603000.0.

  • Rigel Pharmaceuticals' Depreciation & Amortization (CF) fell 130.93% to $603000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 2613.46%. This contributed to the annual value of $2.2 million for FY2024, which is 7996.77% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $603000.0 for Q3 2025, which was down 130.93% from $607000.0 recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $613000.0 in Q2 2024 and a low of $237000.0 during Q1 2022
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $296000.0 (2023), whereas its average is $391578.9.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Depreciation & Amortization (CF) plummeted by 2970.3% in 2022 and then skyrocketed by 10924.66% in 2024.
  • Rigel Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $404000.0 in 2021, then dropped by 29.7% to $284000.0 in 2022, then increased by 3.17% to $293000.0 in 2023, then surged by 106.14% to $604000.0 in 2024, then dropped by 0.17% to $603000.0 in 2025.
  • Its last three reported values are $603000.0 in Q3 2025, $607000.0 for Q2 2025, and $604000.0 during Q1 2025.